Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13174520 | 0.94 | HPGD (0.55) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL7834433 | 0.90 | HPGD (0.55) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL22648884 | 0.89 | HPGD (0.51) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL22648879 | 0.87 | HPGD (0.50) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL27461430 | 0.86 | KDM4E (0.51) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL18711867 | 0.85 | HPGD (0.51) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL15085735 | 0.84 | HPGD (0.57) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL7495704 | 0.84 | KDM4E (0.52) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL7521126 | 0.84 | HPGD (0.50) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL6749268 | 0.84 | HPGD (0.50) | HPGDKDM4EPKMRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741383-A1 | COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025011480-A1 | COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG | 泰励生物科技（上海）有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-6455548-B2 | FOR PROPHYLAXIS AND THERAPY OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020013348-A1 | 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-01-31 | — | — | US | disclosed |
| WO-2001064216-A1 | 4-ALKYL PIPERIDINYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013348-A1 | 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity | CCR1, CCR4, CCR3 | HPGD 2019/4885KDM4E 1758/4885PKM 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.